CIK 0001640266 · Accelerated filer<br>Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-21 | Jorgensen Nathan D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +103,000 | 103,000 | ||
| 2025-02-20 | Carter Todd Alfred Chief Scientific Officer | Sale | −3,305 | $4.26 | $14K | 77,718 |
| 2025-02-20 | Sandrock Alfred President and CEO | Sale | −11,702 | $4.24 | $50K | 296,816 |
| 2025-02-20 | Swartz Robin COO & CBO | Sale | −3,894 | $4.25 | $17K | 98,397 |
| 2025-02-11 | Carter Todd Alfred Chief Scientific Officer | Sale | −5,413 | $4.45 | $24K | 81,023 |
| 2025-02-11 | Swartz Robin COO & CBO | Sale | −6,950 | $4.45 | $31K | 102,291 |
| 2025-02-11 | Sandrock Alfred President & CEO | Sale | −16,644 | $4.45 | $74K | 308,518 |
| 2025-02-11 | Fahey Sandell Jacquelyn Chief Legal Officer | Sale | −4,358 | $4.45 | $19K | 81,643 |
| 2025-01-14 | Swartz Robin COO & CBO | Sale | −3,087 | $5.09 | $16K | 109,241 |
| 2025-01-14 | Carter Todd Alfred Chief Scientific Officer | Sale | −1,191 | $5.13 | $6K | 86,436 |
| 2024-12-23 | Swartz Robin COO&CBO | Sale | −6,500 | $5.65 | $37K | 112,328 |
| 2024-10-02 | Fahey Sandell Jacquelyn Chief Legal Officer | Sale | −5,999 | $5.82 | $35K | 86,001 |
| 2024-10-01 | Jorgensen Nathan D. Chief Financial Officer | Grant or award | +80,000 | 80,000 | ||
| 2024-07-08 | Jorgensen Nathan D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-06-05 | Vitale Nancy Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-05 | SCANGOS GEORGE A Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-05 | PIERCE GLENN Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-05 | Onyia Jude Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-05 | MACKEY CATHERINE J Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-05 | Hyman Steven Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 |
Page 4 of 7 · 130 trades